Category: PMCPA Case of the Week

Cases selected for the AskAnzal weekly PMCPA insight newsletter

8 Mar 2026

AUTH/3613/2/22: Complainant v AstraZeneca β€” LinkedIn promotion allegation and alleged breach of undertaking (out of scope)

Complaint alleged LinkedIn promotion and breach of an undertaking by AstraZeneca. PMCPA concluded the matter was outwith the…

8 Mar 2026

AUTH/3778/6/23: Daiichi Sankyo – unclear declaration of involvement in third‑party AF article

Daiichi Sankyo facilitated an AF digital diagnosis opinion article on an independent news site, but its involvement was…

8 Mar 2026

Theramex: LinkedIn β€˜About Us’ claim breached Code for unqualified use of β€˜safe’

Theramex’s LinkedIn β€˜About Us’ described its solutions as β€œinnovative, effective and safe”. The PMCPA ruled this was misleading…

8 Mar 2026

Procter & Gamble and Sanofi-Aventis: Actonel Combi promotional email and prior consent (AUTH/2111/3/08 & AUTH/2112/3/08)

A GP complained about an allegedly unsolicited promotional email for Actonel Combi. The Panel found the recipient had…

8 Mar 2026

Novo Nordisk diabetes supplement in The Times ruled to be pre-licence promotion of liraglutide to the public

A Times diabetes supplement funded and editorially controlled by Novo Nordisk included trial claims about unapproved liraglutide. The…

8 Mar 2026

Sanofi-Aventis dinner with oncology team ruled out of proportion (AUTH/2236/6/09)

A pharmacist alleged an oncology team dinner was purely social. PMCPA found the three-course meal with wine went…

8 Mar 2026

Norgine v Movetis: β€œA new way out of chronic constipation in women” claim held misleading when unqualified inside leavepiece (Resolor)

Resolor promo used β€œAt last! A new way out of chronic constipation in women”. Appeal Board found no…

8 Mar 2026

Diurnal: β€˜Products and Pipeline’ webpage ruled promotionalβ€”pre-licence pipeline promotion and missing PI/INN for Alkindi (AUTH/3274/10/19)

Health-professional website page combined a licensed product with pipeline products and implied they were β€œeffective, high quality”. PMCPA…

8 Mar 2026

AUTH/3086/9/18 β€” Director v Merck Sharp & Dohme

PMCPA case summary: Director v Merck Sharp & Dohme (AUTH/3086/9/18). Case text not provided in CASE_TEXT, so details…

8 Mar 2026

AstraZeneca v Eli Lilly and Daiichi-Sankyo: Efient leavepiece and 15‑month claims vs 12‑month recommended treatment

Efient leavepiece used prominent 15‑month subgroup/landmark data and downplayed overall bleeding risk. PMCPA ruled it misleading, inconsistent with…

⭐ Flagship Programme

AQP Flagship Path — the complete UK ABPI signatory programme

12 modules. 12 weeks. Final Signatory readiness. The industry standard for ABPI Code signatories — £995 + VAT.

Enrol — AQP Path Learn more

📰 Weekly PMCPA Case Breakdown

One real case. One key lesson. Every week β€” free.

Subscribe Free
🎓 AQP Training